Treating GA with Avacincaptad Pegol: 3.5-Year Data

Show Description +

Dr. Kaiser provides a 3.5-year data update from the GATHER2 open-label extension study of avacincaptad pegol (Izervay, Astellas) for the treatment of geographic atrophy.

Posted: 5/20/2026

Keywords:

retina-meeting-recap

•

GATHER2

•

Clinical Trials

•

avacincaptad pegol

•

astellas

•

izervay

•

IVERIC bio

Up Next

Name: Treating GA with Avacincaptad Pegol: 3.5-Year Data
Uploaded: 2026-05-20T18:46:31+00:00
Description: Dr. Kaiser provides a 3.5-year data update from the GATHER2 open-label extension study of avacincaptad pegol (Izervay, Astellas) for the treatment of geographic atrophy.

A Potential Noninvasive Therapy for Chronic CSC

Claudio Iovino, MD

An Update on MCO-010 Optogenetics Therapy for Advanced RP

Vinit B. Mahajan, MD, PhD

Decreasing Injection Burden for Patients With DME

Katherine E. Talcott, MD

Assessing SHRM With Faricimab Therapy

SriniVas R. Sadda, MD

Using OCT and AI to Evaluate Uveitis

Parisa Emami-Naeini, MD, MPH

Phase 3 Clinical Trial Results for OTX-TKI

Patricio G. Schlottmann, MD

IL-6 Inhibition in Diabetic Macular Edema

Arshad M. Khanani, MD, MA, FASRS, and Roger A. Goldberg, MD

Back to All Videos

Treating GA with Avacincaptad Pegol: 3.5-Year Data

Peter K. Kaiser, MD

Dr. Kaiser provides a 3.5-year data update from the GATHER2 open-label extension study of avacincaptad pegol (Izervay, Astellas) for the treatment of geographic atrophy.

Posted: 5/20/2026

Keywords:

retina-meeting-recap

•

GATHER2

•

Clinical Trials

•

avacincaptad pegol

•

astellas

•

izervay

•

IVERIC bio

Please log in to leave a comment.

Meeting Coverage:

Association for Research in Vision & Ophthalmology

Treating GA with Avacincaptad Pegol: 3.5-Year Data

Up Next

Treating GA with Avacincaptad Pegol: 3.5-Year Data

More From ARVO: 2026 Coverage